Cited 12 times in
Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김동우 | - |
dc.contributor.author | 김세훈 | - |
dc.contributor.author | 김소영 | - |
dc.contributor.author | 윤미진 | - |
dc.contributor.author | 장종희 | - |
dc.date.accessioned | 2018-08-28T17:08:19Z | - |
dc.date.available | 2018-08-28T17:08:19Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0363-9762 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/162292 | - |
dc.description.abstract | PURPOSE: This retrospective study aimed to correlate F-FDG uptake on PET/CT with isocitrate dehydrogenase enzyme isoform 1 (IDH1) mutation in patients with cerebral gliomas. Hierarchical interactions between factors affecting overall survival (OS) were also examined. METHODS: In 59 patients with glioma, the ratio of the SUVmax of a glioma to the SUVmean of the contralateral cortex (G/C ratio) on F-FDG PET/CT and the presence of IDH1 mutation were correlated. The prognostic value of clinicopathologic factors and G/C ratio for OS were assessed using a Cox proportional hazards model and classification and regression tree models. RESULTS: The mean G/C ratio of IDH1-mutant tumors was significantly lower than that of IDH1 wild-type tumors (0.73 vs 1.14, P = 0.004). In multivariate analysis, IDH1-mutant and G/C ratio were significant for OS. The classification and regression tree modeling identified 3 risk groups for OS (group 1: IDH1 mutant [hazard ratio, 0.2]; group 2: G/C ratio </=0.8 with IDH1 wild type [hazard ratio, 0.83]; group 3: G/C ratio >0.8 with IDH1 wild type [hazard ratio, 1.9]) (overall P < 0.001). The mean OS was 37.0 months in group 1, 28.6 months in group 2, and 20.7 months in group 3, respectively, showing significant differences among the groups (group 1 vs group 2: P = 0.023, group 2 vs group 3: P = 0.049, group 1 vs group3: P < 0.001). CONCLUSIONS: F-FDG uptake of IDH1-mutant gliomas was significantly lower than that of IDH1 wild-type gliomas. IDH1 mutation was the most important factor in identifying patients with the best prognosis, whereas increased F-FDG uptake provided additional prognostic information for predicting poor OS among patients with IDH1 wild-type gliomas. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Lippincott | - |
dc.relation.isPartOf | CLINICAL NUCLEAR MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Nuclear Medicine | - |
dc.contributor.googleauthor | Dongwoo Kim | - |
dc.contributor.googleauthor | Soyoung Kim | - |
dc.contributor.googleauthor | Se Hoon Kim | - |
dc.contributor.googleauthor | Jong Hee Chang | - |
dc.contributor.googleauthor | Mijin Yun | - |
dc.identifier.doi | 10.1097/rlu.0000000000002006 | - |
dc.contributor.localId | A05304 | - |
dc.contributor.localId | A00610 | - |
dc.contributor.localId | A05460 | - |
dc.contributor.localId | A02550 | - |
dc.contributor.localId | A03470 | - |
dc.relation.journalcode | J00595 | - |
dc.identifier.eissn | 1536-0229 | - |
dc.identifier.pmid | 29485450 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00003072-201805000-00002&LSLINK=80&D=ovft | - |
dc.contributor.alternativeName | Kim, Dongwoo | - |
dc.contributor.alternativeName | Kim, Se Hoon | - |
dc.contributor.alternativeName | Kim, Soyoung | - |
dc.contributor.alternativeName | Yun, Mi Jin | - |
dc.contributor.alternativeName | Chang, Jong Hee | - |
dc.contributor.affiliatedAuthor | Kim, Dongwoo | - |
dc.contributor.affiliatedAuthor | Kim, Se Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Soyoung | - |
dc.contributor.affiliatedAuthor | Yun, Mi Jin | - |
dc.contributor.affiliatedAuthor | Chang, Jong Hee | - |
dc.citation.volume | 43 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 311 | - |
dc.citation.endPage | 316 | - |
dc.identifier.bibliographicCitation | CLINICAL NUCLEAR MEDICINE, Vol.43(5) : 311-316, 2018 | - |
dc.identifier.rimsid | 59878 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.